Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Plasminogen Activator Type 1 (Af Epitope) antibody

Reactivity: Human IA, InhA Host: Mouse Monoclonal MA-55F4C12 unconjugated
Catalog No. ABIN2192040
  • Target
    Plasminogen Activator Type 1
    Binding Specificity
    Af Epitope
    Reactivity
    Human
    Host
    • 1
    Mouse
    Clonality
    • 1
    Monoclonal
    Conjugate
    • 1
    Un-conjugated
    Application
    Immunoassay (IA), Inhibition Assay (InhA)
    Sterility
    0.2 μm filtered
    Clone
    MA-55F4C12
  • Application Notes
    For inhibition of biological activity dilutions have to be made according to the amounts PAI-1 to be inactivated.
    Restrictions
    For Research Use only
  • Buffer
    PBS, containing 0.1 % bovine serum albumin.
    Storage
    4 °C
    Storage Comment
    Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
    Expiry Date
    12 months
  • Naessens, Gils, Compernolle, Declerck: "Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition." in: Thrombosis and haemostasis, Vol. 90, Issue 1, pp. 52-8, (2003) (PubMed).

    Debrock, Declerck: "Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms." in: Biochimica et biophysica acta, Vol. 1337, Issue 2, pp. 257-66, (1997) (PubMed).

  • Target
    Plasminogen Activator Type 1
    Background
    Plasminogen activator inhibitor type-1 (PAI-1), a member of the serine protease inhibitor (serpin) superfamily is an important protein in the regulation of fibrinolysis. PAI-1 is unique among the serpins because of its functional and conformational flexibility. PAI-1 is the most important physiological inhibitor of both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). Increased PAI-1 levels are associated with thrombotic events and is an established risk factor for cardiovascular diseases. The active conformation PAI-1 inhibits its target proteinases by the formation of a stable, inactive complex. Although PAI-1 is synthesized as an active molecule, it converts spontaneously to an inactive, latent form that can be partially reactivated by denaturing agents. In addition, a third conformation reacting as a non-inhibitory substrate towards various target proteinases has been identified. The epitope of monoclonal antibody MA-55F4C12 is within the stretch of 29 amino acids in PAI-1 (region Glu128-Ala131). Glu128, Val129, Glu130, Arg131 and Lys154 are the major determinants. All five residues act cooperatively in the binding to MA-55F4C12 and constitute the epitope. The epitope of the antibody does not cover the complete alpha-helix F and turn connecting alpha-helix F and beta-strand s3A, but is restricted to the hinge region between alpha-helix F and the main part of the PAI-1 Molecule. The monoclonal antibody MA-55F4C12 is a 'switching' antibody, capable of inducing a non-inhibitory substrate form of PAI-1. The antibody cross reacts with rat and mouse PAI-1.
You are here:
Support